BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Safety of Gadovist in Renally Impaired Patients
Phase 4
Completed
- Conditions
- FibrosisRenal Impairment
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 927
- Registration Number
- NCT00828737
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
Phase 3
Completed
- Conditions
- Premenstrual Dysphoric Disorder ( PMDD)
- Interventions
- Drug: EE20/DRSP(YAZ, BAY86-5300)Drug: Placebo
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 187
- Registration Number
- NCT00824187
YAZ, Oral Contraceptive Registration in China
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: YAZ (SH T00186, BAY86-5300)
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 675
- Registration Number
- NCT00819312
GA YAZ ACNE in China Phase III
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: EE20/Drospirenone (YAZ, BAY86-5300)Drug: Placebo
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 179
- Registration Number
- NCT00818519
Naproxen Sodium ER Pharmacokinetic Study
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Naproxen sodium ER (BAYH6689)Drug: Commercial Naproxen (Aleve, BAYH6689)
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00818415
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3371
- Registration Number
- NCT00812175
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Phase 3
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 445
- Registration Number
- NCT00810693
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens
Phase 2
Completed
- Conditions
- Ovulation Inhibition
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)Drug: EV/DNG (SH T00658L)
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 209
- Registration Number
- NCT00805415
- Locations
- 🇳🇱
Dinox B.V., Groningen, Netherlands
🇩🇪Dinox GmbH Berlin, Berlin, Germany
Scandinavian Mirena Insertion Nulliparous Trial.
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 224
- Registration Number
- NCT00798980
INSIGHT - Post Marketing Surveillance
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 791
- Registration Number
- NCT00792350
© Copyright 2025. All Rights Reserved by MedPath